Enliven Posts Loss Beat and Cash Surge
Enliven Therapeutics ( NASDAQ:ELVN ) , a clinical-stage biotechnology company focused on cancer therapies, reported its second quarter 2025 results on August 13, 2025. The release highlighted a net loss per share of $ ( 0.49 ) for Q2 2025 ( GAAP ) , a result that modestly beat the analyst ...
Can Enliven Therapeutics, Inc. ( ELVN ) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday - Axos Financial ( NYSE:AX ) , Chipotle Mexican Grill ( NYSE:CMG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut TEGNA Inc. TGNA price target from $22 to $21. Guggenheim analyst Curry Baker maintained a ...
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Collective Mining ( AMEX:CNL ) , Celcuity ( NASDAQ:CELC )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday. Shares of The Greenbrier Companies, Inc. GBX fell sharply in today's pre-market trading as the company posted downbeat results for its second quarter.
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - ( ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird analyst Brian Skorney initiated coverage on Alumis Inc.
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference ...
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - Enliven Therapeutics ( NASDAQ:ELVN )
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% ( 8/18 ) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - Enliven Therapeutics ( NASDAQ:ELVN )
BOULDER, Colo., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- Enliven Therapeutics, Inc. ( Enliven or the Company ) ELVN, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ...
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
BOULDER, Colo., Sept. 18, 2024 ( GLOBE NEWSWIRE ) -- Enliven Therapeutics, Inc. ( Enliven or the Company ) ( Nasdaq: ELVN ) , a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the ...
Why Is Enliven Therapeutics Stock Trading Higher On Monday? - Enliven Therapeutics ( NASDAQ:ELVN )
HC Wainwright initiated coverage on Enliven Therapeutics, Inc. ELVN and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and liquid tumor indications.
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. ( ELVN ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 58.8% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Wall Street Analysts Think Enliven Therapeutics, Inc. ( ELVN ) Could Surge 43.04%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program Why Is Enliven Therapeutics Stock Trading Higher Today? - Enliven Therapeutics ( NASDAQ:ELVN )
Thursday, Enliven Therapeutics Inc ELVN released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia ( CML ) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors ( TKIs ) .
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Janux Therapeutics ( NASDAQ:JANX ) , Alpine Immune Sciences ( NASDAQ:ALPN ) , Enliven Therapeutics ( NASDAQ:ELVN )
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. ELVN rose sharply during Thursday's session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Achieved initial cumulative MMR rate of 44% ( 7/16 ) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved ...
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - Enliven Therapeutics ( NASDAQ:ELVN )
BOULDER, Colo., April 09, 2024 ( GLOBE NEWSWIRE ) -- Enliven Therapeutics, Inc. ( Enliven or the Company ) ELVN, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori ...
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says - Enliven Therapeutics ( NASDAQ:ELVN )
Mizuho Securities initiated coverage on Enliven Therapeutics Inc ELVN, a clinical-stage precision oncology company focused on discovering and developing next-generation small molecule kinase inhibitors.
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday - Nordstrom ( NYSE:JWN ) , Core & Main ( NYSE:CNM ) , National CineMedia ( NASDAQ:NCMI )
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Shares of National CineMedia, Inc. NCMI jumped 25.5% to $5.30 after the company posted upbeat results for its fourth quarter and disclosed a new $100 million share repurchase program.
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates - Enliven Therapeutics ( NASDAQ:ELVN )
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002
IO Biotech Announces 2023 Third Quarter Results - IO Biotech ( NASDAQ:IOBT )
Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® ( pembrolizumab ) , in patients with advanced melanoma
IO Biotech Announces 2023 Third Quarter Results
• Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® ( pembrolizumab ) , in patients with advanced melanoma • Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 ...
Enliven Therapeutics Insider Trades Send a Signal - Enliven Therapeutics ( NASDAQ:ELVN )
AM Partners VI LLC, 10% Owner at Enliven Therapeutics ELVN, reported a large insider sell on September 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that LLC sold 197,500 shares of Enliven Therapeutics.
10% Owner At This Health Care Company Sells $7.04M of Stock - Enliven Therapeutics ( NASDAQ:ELVN )
AM Partners VI LLC, 10% Owner at Enliven Therapeutics ELVN, reported a large insider sell on August 28, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that LLC sold 440,000 shares of Enliven Therapeutics.
Westlake Village BioPartners Launches $450 Million Fund and Appoints Next Generation of Leaders
Firm's oversubscribed third fund brings total raised to $1.3 billion since founding in September 2018 LOS ANGELES, July 17, 2023 /PRNewswire/ -- Westlake Village BioPartners ( "Westlake" ) today announced the launch of its third fund of $450 million to incubate and grow early stage ...
Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
BERKELEY, Calif., June 06, 2023 ( GLOBE NEWSWIRE ) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer ( COO ) and Chief ...
3 Stocks in the Limelight on New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).
